- Stocks
- Pharma & Healthcare
- Poly Medicure
Poly Medicure share price
NSE: POLYMEDPharma & HealthcareMedical Instruments & Supplies
Poly Medicure at a glance
Poly Medicure (NSE: POLYMED) closed at ₹1,479.10 on 22 Oct 2026, up 1.31% on the day. With a market capitalisation of ₹14,992 Cr, it ranks 423rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.
At its last close the stock traded at 46.7× trailing earnings, against a return on equity of 10.4% in FY26. Over the past year the share price has fallen 20.5%. Its 52-week range is ₹1,182.00 (30 Mar 2026) to ₹2,094.30 (11 Nov 2025); the last close is 29.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹535 Cr (+21.3% year on year) and net profit ₹63 Cr (−29.3%), on a consolidated basis. Promoters held 62.42% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹14,992 CrRank 423 on NSE
- P/E (trailing)
- 46.7×
- Price to book
- 3.89×FY26
- EPS (TTM)
- ₹31.79to Q4 FY26
- ROE
- 10.4%FY26
- ROCE
- 13.4%FY26
- Debt to equity
- 0.11FY26
- Net profit margin
- 16.8%FY26
- Book value / share
- ₹306.45FY26
- 52-week high
- ₹2,094.3011 Nov 2025
- 52-week low
- ₹1,182.0030 Mar 2026
- 1-year return
- −20.5%
- RSI (14-day)
- 29.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.31% | −6.3% | −13.9% | −11.2% | −20.5% |
Poly Medicure quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹385 Cr | ₹420 Cr | ₹424 Cr | ₹441 Cr | ₹403 Cr | ₹444 Cr | ₹494 Cr | ₹535 Cr |
| Revenue YoY | +19.9% | +24.5% | +24.9% | +16.6% | +4.8% | +5.7% | +16.4% | +21.3% |
| Net profit | ₹74 Cr | ₹87 Cr | ₹84 Cr | ₹90 Cr | ₹92 Cr | ₹91 Cr | ₹69 Cr | ₹63 Cr |
| Net profit YoY | +18.1% | +40.6% | +28.4% | +31.0% | +23.9% | +3.9% | −17.2% | −29.3% |
| Net margin | 19.2% | 20.8% | 19.7% | 20.3% | 22.8% | 20.5% | 14.0% | 11.8% |
| EPS | ₹7.71 | ₹9.01 | ₹8.48 | ₹8.92 | ₹9.19 | ₹9.06 | ₹7.00 | ₹6.54 |
Poly Medicure financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹786 Cr | ₹923 Cr | ₹1,115 Cr | ₹1,376 Cr | ₹1,670 Cr | — |
| Operating profit | ₹177 Cr | ₹193 Cr | ₹236 Cr | ₹342 Cr | ₹447 Cr | — |
| Net profit | ₹133 Cr | ₹144 Cr | ₹177 Cr | ₹256 Cr | ₹333 Cr | — |
| EPS (₹) | ₹15.00 | ₹15.00 | ₹19.00 | ₹27.00 | ₹34.00 | — |
| Cash from operations | ₹119 Cr | ₹123 Cr | ₹191 Cr | ₹266 Cr | ₹240 Cr | — |
| Total debt | ₹63 Cr | ₹38 Cr | ₹18 Cr | ₹1 Cr | ₹0 Cr | ₹52 Cr |
| Shareholders' equity | ₹966 Cr | ₹1,087 Cr | ₹1,242 Cr | ₹1,470 Cr | ₹2,766 Cr | ₹3,106 Cr |
Poly Medicure shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 62.44% | 62.44% | 62.42% | 62.42% | 62.42% | 62.42% |
| Foreign institutions | 11.46% | 11.41% | 9.77% | 9.40% | 5.91% | 5.57% |
| Domestic institutions | 11.96% | 11.72% | 13.54% | 13.84% | 15.59% | 16.08% |
| Non-institutions | 14.15% | 14.44% | 14.27% | 14.34% | 16.08% | 15.94% |
Poly Medicure vs peers
The listed Pharma & Healthcare companies nearest to Poly Medicure by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALIVUSAlivus Life Sciences | ₹1,272.00 | +0.82% | +37.5% | ₹15,612 Cr | 27.7 | 17.2% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −0.41% | −14.0% | ₹15,430 Cr | 22.9 | 11.2% |
| ASTRAZENAstraZeneca Pharma India | ₹6,056.00 | −0.38% | −33.5% | ₹15,140 Cr | 80.9 | 15.0% |
| POLYMEDPoly Medicure | ₹1,479.10 | +1.31% | −20.5% | ₹14,992 Cr | 46.7 | 10.4% |
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹14,966 Cr | 47 | 6.5% |
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,826 Cr | 37.1 | 13.4% |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,553 Cr | 100 | 6.6% |
Ask anything about Poly Medicure
Pivot answers on the live chart with evidence you can check, and tests strategies against POLYMED's own history. Try: “Why has POLYMED moved over the last three months?” · “Backtest a 50-day moving-average crossover on POLYMED over five years” · “Compare POLYMED with ALIVUS on margins and valuation”
Frequently asked questions about Poly Medicure
What is the share price of Poly Medicure today?
Poly Medicure (NSE: POLYMED) last closed at ₹1,479.10 on 22 Oct 2026. Its 52-week high is ₹2,094.30 and its 52-week low is ₹1,182.00.
What is the market cap of Poly Medicure?
Poly Medicure's market capitalisation is ₹14,992 Cr (₹14,992 Cr) at the 22 Oct 2026 close, ranking 423rd among the NSE companies Pivot tracks.
What is the P/E ratio of Poly Medicure?
Poly Medicure trades at a trailing P/E of 46.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 47.
What is the ROE and ROCE of Poly Medicure?
Return on equity was 10.4% in FY26 and return on capital employed was 13.4% in FY26 (consolidated figures).
Is Poly Medicure a debt-free company?
No. Poly Medicure's debt-to-equity ratio was 0.11 in FY26, with total debt of ₹52 Cr.
What were Poly Medicure's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Poly Medicure reported revenue of ₹535 Cr, +21.3% year on year, and net profit of ₹63 Cr, −29.3% year on year.
How has Poly Medicure stock performed over the last year?
Poly Medicure's share price has fallen 20.5% over the past year, −11.2% over three months and −13.9% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Poly Medicure?
As of 30 Jun 2026: promoters 62.42%, foreign institutions 5.57%, domestic institutions 16.08%, non-institutions 15.94%.
Who are Poly Medicure's competitors?
The listed Pharma & Healthcare companies closest to Poly Medicure by market cap are Alivus Life Sciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Syngene International, Jubilant Pharmova and Dr. Agarwal's Health Care.
Is Poly Medicure a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Poly Medicure's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on POLYMED against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text